Search company, investor...

Elusys Therapeutics

Founded Year



Acquired | Acquired

Total Raised


About Elusys Therapeutics

Elusys Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of targeted anti-infective therapeutics using Heteropolymer (HP) Antibodies for the treatment of infectious disease. The company's Heteropolymer Antibody Technology has demonstrated a ability to clear and destroy pathogens and aims to provide a platform to develop a deep pipeline of drug candidates targeted against bacterial, viral and fungal infections. On December 21st, 2021, Elusys Therapeutics was acquired by Heat Biologics. The terms of the transaction were not disclosed.

Headquarters Location

25 Riverside Drive 25 Riverside Drive

Pine Brook, New Jersey, 07058,

United States


Missing: Elusys Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Elusys Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Elusys Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Elusys Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Elusys Therapeutics Patents

Elusys Therapeutics has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Ion channel toxins, Bacterial toxins, Neurotoxins, Invertebrate toxins


Application Date


Grant Date



Related Topics

Transcription factors, Ion channel toxins, Bacterial toxins, Neurotoxins, Invertebrate toxins



Latest Elusys Therapeutics News

Biodefense Market to Witness Massive Growth in Years to Come

Mar 27, 2023

News Provided By Share This Article Biodefense Stay up-to-date with Global Biodefense Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. HTF Market Intelligence consulting is uniquely positioned empower and inspire with research and consulting services to empower businesses with growth strategies, by offering services.” — Craig Francis PUNE, MAHARASHTRA, INDIA, March 27, 2023/ / -- The Latest Released Biodefense market study has evaluated the future growth potential of Biodefense market and provides information and useful stats on market structure and size. The report is intended to provide market intelligence and strategic insights to help decision-makers take sound investment decisions and identify potential gaps and growth opportunities. Additionally, the report also identifies and analyses changing dynamics, and emerging trends along with essential drivers, challenges, opportunities, and restraints in the Biodefense market. The study includes market share analysis and profiles of players such as XOMA Corporation (United States), SIGA Technologies (New York), Elusys Therapeutics Inc (United States), Cleveland Biolabs (United States), Ology Bioservice (United States), Emergent Biosolutions Inc (United States), Ichor Medical System (United States), Scorpion Biological Services (United States), DynPort Vaccine Company (South Africa), AstraZeneca Plc (United Kingdom). If you are a Biodefense manufacturer and would like to check or understand the policy and regulatory proposals, designing clear explanations of the stakes, potential winners and losers, and options for improvement then this article will help you understand the pattern with Impacting Trends. Click To get SAMPLE PDF (Including Full TOC, Table & Figures) According to HTF Market Intelligence, the Global Biodefense market to witness a CAGR of 4.2% during forecast period of 2023-2029. The market is segmented by Application (Civilian non-combatant, Military combatant) by Type (Anthrax, Smallpox, Botulism, Radiation/Nuclear) and by Geography (North America, South America, Europe, Asia Pacific, MEA). Definition: Biodefense refers to the practices, strategies, and technologies used to prevent, detect, and respond to biological threats, such as disease outbreaks, bioterrorism, and biological warfare. These threats can arise from natural occurrences, accidental releases, or deliberate acts of terrorism or warfare.Biodefense efforts are typically coordinated by government agencies, such as the Centers for Disease Control and Prevention (CDC) and the Department of Homeland Security (DHS), in collaboration with public health organizations, research institutions, and other stakeholders. These efforts require interdisciplinary collaboration, including scientists, public health officials, law enforcement, emergency responders, and other professionals. Revenue and Sales Estimation — Historical Revenue and sales volume are presented and further data is triangulated with top-down and bottom-up approaches to forecast complete market size and to estimate forecast numbers for key regions covered in the report along with classified and well-recognized Types and end-use industry. SWOT Analysis on Biodefense Players In addition to Market Share analysis of players, in-depth profiling, product/service, and business overview, the study also concentrates on BCG matrix, heat map analysis, FPNV positioning along with SWOT analysis to better correlate market competitiveness. Demand from top-notch companies and government agencies is expected to rise as they seek more information on the latest scenario. Check the Demand Determinants section for more information. Regulation Analysis • Regulation and its Implications FIVE FORCES & PESTLE ANALYSIS: In order to better understand market conditions five forces analysis is conducted that includes the Bargaining power of buyers, Bargaining power of suppliers, Threat of new entrants, Threat of substitutes, and Threat of rivalry. • Political (Political policy and stability as well as trade, fiscal, and taxation policies) • Economical (Interest rates, employment or unemployment rates, raw material costs, and foreign exchange rates) • Social (Changing family demographics, education levels, cultural trends, attitude changes, and changes in lifestyles) • Technological (Changes in digital or mobile technology, automation, research, and development) • Legal (Employment legislation, consumer law, health, and safety, international as well as trade regulation and restrictions) • Environmental (Climate, recycling procedures, carbon footprint, waste disposal, and sustainability) Heat map Analysis, 3-Year Financial and Detailed Company Profiles of Key & Emerging Players: XOMA Corporation (United States), SIGA Technologies (New York), Elusys Therapeutics Inc (United States), Cleveland Biolabs (United States), Ology Bioservice (United States), Emergent Biosolutions Inc (United States), Ichor Medical System (United States), Scorpion Biological Services (United States), DynPort Vaccine Company (South Africa), AstraZeneca Plc (United Kingdom). Geographically, the following regions together with the listed national/local markets are fully investigated: • APAC (Japan, China, South Korea, Australia, India, and the Rest of APAC; the Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) • Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) • North America (U.S., Canada, and Mexico) • South America (Brazil, Chile, Argentina, Rest of South America) • MEA (Saudi Arabia, UAE, South Africa) Some Extracts from Biodefense Market Study Table of Content Biodefense Market Size (Sales) Market Share by Type (Product Category) [Anthrax, Smallpox, Botulism, Radiation/Nuclear] in 2023 Biodefense Market by Application/End Users [Civilian non-combatant, Military combatant] Global Biodefense Sales and Growth Rate (2019-2029) Biodefense Competition by Players/Suppliers, Region, Type, and Application Biodefense (Volume, Value, and Sales Price) table defined for each geographic region defined. Supply Chain, Sourcing Strategy and Downstream Buyers, Industrial Chain Analysis ........and view more in complete table of Contents Check it Out Complete Details os Report @ Thanks for reading this article; you can also get individual chapter-wise sections or region-wise reports like Balkan, China-based, North America, Europe, or Southeast Asia. Criag Francis

Elusys Therapeutics Frequently Asked Questions (FAQ)

  • When was Elusys Therapeutics founded?

    Elusys Therapeutics was founded in 1998.

  • Where is Elusys Therapeutics's headquarters?

    Elusys Therapeutics's headquarters is located at 25 Riverside Drive, Pine Brook.

  • What is Elusys Therapeutics's latest funding round?

    Elusys Therapeutics's latest funding round is Acquired.

  • How much did Elusys Therapeutics raise?

    Elusys Therapeutics raised a total of $65.32M.

  • Who are the investors of Elusys Therapeutics?

    Investors of Elusys Therapeutics include Nighthawk Biosciences, Eagle Advisors, MedImmune Ventures, Crescendo Ventures, Invesco Private Capital and 4 more.

  • Who are Elusys Therapeutics's competitors?

    Competitors of Elusys Therapeutics include Affibody, GangaGen, Arcion Therapeutics, Sonexa Therapeutics, Anadys Pharmaceuticals and 15 more.

Compare Elusys Therapeutics to Competitors

Athersys Logo

Athersys develops biotechnology-based therapeutics.


Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.

Pulmotect Logo

Pulmotect develops host-directed or pathogen-agnostic products to reduce morbidity and mortality in patients at risk of severe respiratory diseases. It offers immunomodulatory and pathogen-agnostic approaches to prevent and treat respiratory complications. The company was founded in 2007 and is based in Houston, Texas.

Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.


Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.


Affibody is a private clinical-stage biotech company. It specializes in the discovery of antibody mimetics that provide biodistribution flexibility, tissue penetration, and tumor targeting. The company was founded in 1998 and is based in Solna, Sweden.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.